Tinoridines’ association with HTR4 adds indications for treating gastrointestinal disorders28, whereas Nicergoline interaction with CHRM3 indicates potential uses for treating Alzheimer’s disease and schizophrenia29 and at the same time adds a potential mechanism of action to Nicergoline’s primary use, as CHRM3 is directly tied to blood-pressure control30. The gene discussed is HTR4; the disease is early-onset autosomal dominant Alzheimer disease.